CV Sciences Inc (CVSI)

[Wolf-man jack]

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149516464

In September, the Boston-based Ginkgo Bioworks, which calls itself “the organism company”, landed a deal worth approximately $100m with Cronos Group, one of Canada’s most prominent cannabis companies. Ginkgo promises to produce the active ingredients in marijuana from genetically modified microorganisms, such as yeast. The company says its process, which draws on the field of synthetic biology, will produce a far greater array of valuable compounds at greater purity and for less money than marijuana plants can.

In brewing beer, yeast functions essentially as a factory, converting sugar into alcohol. Ginkgo plans to modify the DNA of yeast (or another microorganism) so its enzymes convert a “soup” of sugar, vitamins, nitrogen and other ingredients into THC, CBD and other chemicals found in marijuana. Instead of growing on farms, the chemicals will be produced in giant metal vats, like the ones at breweries.

https://finance.yahoo.com/news/cronos-group-names-todd-abraham-153554537.html

Why It's Important
Abraham’s hiring, as a result of his past successes in consumer-packaged goods, is a strong indicator of Cronos prioritizing the consumer experience.

"The work Cronos Group has underway with Ginkgo Bioworks and Cronos Device Labs is just the beginning," he said in the press release. "I look forward to leveraging my consumer products experience, technical expertise, and scientific background to help drive Cronos Group’s cannabinoid technology and product development across categories."

https://globenewswire.com/news-release/2019/05/07/1818293/0/en/Cronos-Group-Opens-Cronos-Device-Labs-New-Global-R-D-Center-in-Israel.html

The launch of Cronos Device Labs is an exciting next step on our journey to become a leader in cannabinoid innovation,” said Cronos Group's Mike Gorenstein, Chairman, President and Chief Executive Officer. “Vapor is already one of the most popular forms of cannabis consumption, and we see a clear opportunity for Cronos Group to introduce the next-generation of vaporizer products designed specifically for cannabinoid formulations. With a deep bench of engineering, analytical, scientific and design talent already in place, we are confident that Cronos Device Labs will play an important role in positioning the Company for long-term success by enabling us to build innovative vaporizer products that resonate with our customers and generate shareholder value.”

“The vaporization space is rapidly evolving,” added Arye Weigensberg, General Manager at Cronos Device Labs. “Now, more than ever, consumers are migrating to this convenient consumption method. At the same time, the category remains in its infancy with few products that deliver full spectrum effects in a consistent and controlled manner. Our mission at Cronos Device Labs is to develop a line of vaporizers and formulations that truly bring cannabis benefits into full expression.”